IL2 and Dravet syndrome: Global analysis of transcriptome changes revealed that tofacitinib treatment reverses the dysregulation of many gene signatures observed in DS, effectively attenuating many pro-inflammatory signatures beyond IFN gamma and alpha responses, such as Inflammatory Response, TNF-α signaling via NFkB, IL-2 STAT5 signaling, and IL-6 JAK STAT3 signaling (Figure 6 – figure supplement 1c).